Clinical trials: Pneumococcal Infectious Diseases
Acute Otitis Media, Mastoiditis
Impact of Prevnar 13 on Ear Infections in Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
- Trial name
- NCT01272999
- Testing
- No intervention
- Where
- 8 sites in United States
- Volunteers
- 391 people
- Sponsor
- Pfizer
Infectious Disease
Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7
Pneumonia is one of the most prevalent diseases in infants and children. The incidence of pneumonia in children less than 5 years old is about 34-40 cases per 1000 in Europe and America and more than 2 million children die of…
- Trial name
- NCT02040402
- Testing
- 7-valent pneumococcal conjugated vaccine
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Immunization; Infection, Influenza
Seasonal Influenza and Pneumococcal Vaccination in the Elderly
The elderly population and individuals with chronic diseases are at high risk for influenza and influenza-related pneumonia, and it is emphasized that taking pneumonia and influenza vaccine together is effective in reducing…
- Conditions
- Immunization; Infection, Influenza, Pneumonia, Vaccine Refusal
- Trial name
- NCT05661890
- Where
- Turkey (Türkiye)
- Volunteers
- 1,166 people
- Sponsor
- Lokman Hekim University
Pneumococcal Infection
A Retrospective Epidemiological Study on Pneumococcal Infection in Children in Ministry of Health Hospital at EHSA Region in the Eastern Province
The purpose of this study is to establish retrospectively the incidence rates of invasive pneumococcal disease in children aged less than 5 years.
- Trial name
- IPD in saudi (NCT00844467)
- Testing
- serotypes and resistance
- Volunteers
- 300 people
- Sponsor
- King Saud University
Diphtheria, Tetanus
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when…
- Conditions
- Diphtheria, Tetanus, Haemophilus Infection, Pertussis
- Trial name
- NCT00772928
- Testing
- Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
- Where
- 23 sites in United States
- Volunteers
- 1,167 people, healthy volunteers welcome
- Sponsor
- Sanofi
Streptococcus Pneumoniae Infection, Respiratory Syncytial Virus Infections
Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus
This household-based prospective cohort study aims to stablish the household transmission of Respiratory syncytial virus and S. pneumoniae especially in the elderly and infants/children as well as inter-relationship between S.
- Trial name
- NCT05017519
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Influenza
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
The purpose of this study is to investigate the immunogenicity and safety when GSK Biologicals' influenza vaccine Influsplit™ Tetra (Fluarix™ Tetra) is co-administered with Merck \& Co.
- Trial name
- NCT02218697
- Testing
- Influsplit™ Tetra (Fluarix™ Tetra), Pneumovax™ 23
- Where
- 6 sites in Belgium, France
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcus Pneumonia, Controlled Human Infection
Experimental Human Pneumococcal Challenge With SPN3
The 'Experimental Human Pneumococcal challenge' (EHPC) model is a way of putting drops of bacteria into the nose. Investigators have studied this model of putting bacteria in the nose safely in over 1500 volunteers over the past…
- Trial name
- Challenge3 (NCT05535868)
- Testing
- Serotype 3 Experimental Human Pneumococcal Challenge - Liverpool Isolate (LIV014-S3), Serotype 3 Experimental Human Pneumococcal Challenge - Malawi Isolate (MLW-10V)
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Pneumonia
A Polymerase Chain Reaction (PCR) - Based Method to Improve Antibiotic Prescribing for Pneumonia
Pneumonia, or lung infection, is usually treated with antibiotics targeted against the organisms that the physician guesses are causing the problem. The determination of the exact cause of a patient's pneumonia is difficult.
- Trial name
- NCT00867841
- Testing
- nasopharyngeal swab
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Children's Hospital of Eastern Ontario
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Adults Aged ≥18 Years
A Phase Ib/II clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24)developed by Sinovac Life Science Co., Ltd will be conducted in adults aged ≥18 years.
- Trial name
- NCT07543198
- Testing
- Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24
- Where
- China
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
HIV-1-infection, Human Immunodeficiency Virus
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
- Conditions
- HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
- Trial name
- NCT03729778
- Testing
- Prevnar-13
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VA Eastern Colorado Health Care System
Pneumococcal Infectious Disease
Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase II clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.
- Trial name
- NCT06678620
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3
- Where
- 2 sites in China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Acute Lymphoblastic Leukemia, Pediatric
Vaccine Immune Recovery After Leukemia
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia…
- Trial name
- VIRAL (NCT05622682)
- Testing
- Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
- Where
- 6 sites in United States
- Volunteers
- 89 people
- Sponsor
- Children's Hospital of Philadelphia
Pneumococcal Infection
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as…
- Trial name
- STRIDE-13 (NCT06177912)
- Testing
- V116, PPSV23
- Where
- 92 sites in United States, Canada and 11 more
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
Thalassemia, Pneumococcal Infection
Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia
Splenectomized thalassemia major subjects were provided with PCV pneumococcal vaccine (Prevenar 13®) at the start of the trial, following which they were randomly assigned to 2 groups (zinc and placebo group).
- Trial name
- NCT03095326
- Testing
- Zinc, Sucrose, PCV Vaccine
- Where
- Indonesia
- Volunteers
- 56 people
- Sponsor
- Fakultas Kedokteran Universitas Indonesia
Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease
Understanding Pneumococcal Carriage and Disease 2017-2020
Streptococcus pneumoniae is a type of bacteria that is carried (lives) in the nose of most individuals and can sometimes go on to cause severe infections such as meningitis and pneumonia.
- Conditions
- Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae, Invasive Disease, Streptococcal Pneumonia
- Trial name
- NCT03102840
- Testing
- Nasopharyngeal swab, blood sampling
- Where
- United Kingdom
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3…
- Trial name
- NCT03384589
- Testing
- PCV13
- Where
- Canada
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Pneumococcal Infectious Diseases
Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
A newly 23-valent pneumococcal polysaccharide vaccine was developed with promising safety and immunogenicity demonstrated in the phase III trial in China.
- Trial name
- NCT02285036
- Testing
- vaccination PPV23, vaccination PNEUMOVAX 23
- Where
- China
- Volunteers
- 1,660 people
- Sponsor
- Walvax Biotechnology Co., Ltd.
Pneumococcal Infection, ANCA-associated Vasculitis
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Descriptive study of the residual anti-pneumococcal immunity in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who have previously gone through pneumococcal immunization.
- Trial name
- NCT02463539
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infection, Lung Parenchyma
Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals
Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact.
- Trial name
- PPAC (NCT05661513)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France